Deregulated nutrient sensing
Your cells run four molecular "fuel gauges" that read how much food is around and decide whether to grow and store or to repair and recycle, and with age that decision drifts toward "grow." Turning the growth side down lengthens life in worms, flies and mice; in people the evidence is mostly biomarkers, the few clinical tests are mixed, and the main ways of pulling these levers come with costs to muscle and reserve.
Eat with restraint, avoid grazing around the clock, and exercise regularly. Don't chase maximal suppression: keep enough protein and do resistance training, more so as you age. Rapamycin, metformin and NAD⁺ boosters have no trial showing they slow human aging.
Four fuel gauges: two say grow, two say repair
Deregulated nutrient sensing is one of the twelve hallmarks of aging, and the one where diet meets the rate of biological aging. The cell constantly measures the energy and nutrients available and uses that reading to balance anabolism (building and storing) against catabolism (breaking down and repairing).[1]
Four interconnected networks do the measuring. Two read abundance: insulin/IGF-1 signalling, which tracks glucose, and mTOR, which tracks amino acids. Two read scarcity: AMPK and the sirtuins both detect low energy.[2] That gives a convenient accelerator pair and brake pair, though the split is a simplification, because the four are tightly cross-linked by feedback loops.[3]
- Insulin and insulin-like growth factor 1 (IGF-1) signalling is the most evolutionarily conserved aging-control pathway. Among its many targets are the FOXO (forkhead box O) proteins, the switch that matters most for longevity in worms and flies.[4]
- mTOR (mechanistic target of rapamycin) is the master growth hub. It reads amino acids and growth factors and ramps up protein and fat synthesis while shutting down recycling.[5]
- AMPK (AMP-activated protein kinase) is the low-fuel sensor. When energy runs low it inhibits mTOR and triggers autophagy, the cell's recycling, and the building of new mitochondria.[6]
- Sirtuins, a family of seven repair enzymes, need NAD⁺ (nicotinamide adenine dinucleotide) to work, which ties them to the cell's metabolic state and to mitochondrial health.[7] NAD⁺ falls with age in mice, but in people the picture depends on where you measure: lower in older muscle, remarkably stable in whole blood.[8][9]
The governing idea of the field is that growth signalling accelerates aging and that turning nutrient signalling down extends life.[10] In youth the same signalling drives useful building; it takes on pro-aging properties in adulthood.[11]
With age, the swing between growth and repair flattens
Overeating switches on the abundance sensors, inhibits the scarcity sensors, and suppresses the cell's stress responses, including autophagy, antioxidant defence and DNA repair. Fasting and dietary restriction do the reverse.[12] That wiring is well mapped in cells and animals. The idea that health depends on a regular swing between the two states, and that aging flattens it, is a reasonable reading of the wiring, not something measured in people.
With age, and with constant grazing, the swing gives way to chronic metabolic overdrive: insulin/IGF-1 and mTOR idle high, AMPK and sirtuin activity fall, and the cell stays in grow-and-store mode.[13] Two enzymes drain the NAD⁺ that sirtuins need: PARP1, a DNA-damage sensor that may burn more of it as damage builds up, and CD38, whose levels rise in the tissues of old mice and humans, possibly driven by chronic low-grade inflammation.[14][15] Persistent mTOR activity also suppresses autophagy, so damaged components and leaked mitochondrial DNA accumulate, inflame tissue and further deafen cells to insulin: a self-reinforcing loop into inflammaging.[16]
Insulin is the part you can measure
Most of this hallmark is invisible from outside; one arm is not. As insulin clearance falls with age, the body runs chronically high insulin, which keeps the accelerator pressed.[17] That drift shows up in insulin sensitivity well before blood sugar reaches the diabetic range. Among 6,538 British civil servants followed for a median of 9.7 years, the 505 who developed type 2 diabetes saw their insulin sensitivity fall steeply over the 5 years before diagnosis, while their fasting glucose crept up slowly and climbed steeply only in the last 3.[18]
So fasting insulin, and the HOMA-IR score calculated from fasting insulin and glucose together, is the most direct window a routine blood test gives on this hallmark. It is a window, not a verdict: across 7 cohort studies of 26,976 adults without diabetes, the highest HOMA-IR group had about a third higher death rate than the lowest, while fasting insulin on its own fell just short of a clear link.[19] How to interpret the numbers is on midlife labs; the physiology of losing and regaining the feed–fast swing is on metabolic flexibility.
Less growth signalling helps animals, but not down to zero
Mutations that reduce insulin/IGF-1 or mTOR signalling are among the most reproducible longevity levers in biology, lengthening life in worms, flies and mice.[20] But more suppression is not simply better. Shutting the pathway off entirely is incompatible with life: mice lacking either of its two core kinases die as embryos.[21]
In people, observational studies suggest a U-shape, with risk at both ends. Pooling 19 cohort studies of 30,876 adults, those with low IGF-1 had about a third higher all-cause mortality and those with high IGF-1 about a quarter higher than those in the middle.[22] In 380,997 UK Biobank adults with no history of cancer, cardiovascular disease or diabetes, the lowest tenth of IGF-1 carried about 39% higher mortality and the highest tenth about 17% higher.[23] These are associations, not proof that moving IGF-1 changes risk.
Aging muscle shows what the low end looks like: it develops anabolic resistance, needing more amino acids to switch on growth signalling, a major cause of age-related muscle loss.[24] That is the tension behind protein: less protein keeps mTOR quiet, but enough protein preserves muscle. The textbook story that leucine, the most potent mTOR trigger, links protein to aging turns out to be too simple, as the amino-acid results below show.[25]
Eating less: strong in animals, modest and costly in people
Reducing calories without malnutrition is the most reproducible lifespan-extending intervention across species, turning the accelerators down and the brakes up.[26] In people, there are only biomarker results.
The CALERIE trial randomised 220 healthy adults without obesity to a 25% calorie-restriction target or normal eating for two years. It improved cardiometabolic markers, but not all the weight lost was fat: the restricted group lost about 7.6 kg, including about 2.0 kg of lean mass, roughly in proportion to the weight lost;[27] absolute leg strength fell, though strength per kilogram of body weight rose;[28] and bone mineral density dropped modestly at the spine and hip.[29] It slowed one methylation clock, DunedinPACE, by roughly 2–3%, a real but small shift. That analysis was post hoc, people achieved only about 12% restriction against the 25% target, and the other clocks tested, including PhenoAge and GrimAge, did not change significantly.[30] In a later analysis, the participants who regained more than 5% of their weight lost the improvements in insulin and IGF-1 signalling, an association from grouping people by weight change rather than by randomised arm.[31]
Fasting-mimicking diets are short, structured low-calorie, low-protein cycles meant to deliver the same signal without chronic deprivation. One secondary analysis of two randomised trials linked three monthly cycles to lower insulin resistance and liver fat and a roughly 2.5-year drop in a biological-age score, independent of weight loss.[32] The score is a composite of seven routine readings, not a methylation clock, and the improvement tracked changes in four of its own inputs; between 21% and 31% of people on the diet came out biologically older; and two authors hold equity in the company that supplied the diet. Two later single-cycle pilot trials, both with company involvement, confirmed short-term drops in fasting glucose (and, in one, IGF-1) but did not measure biological age.[33][34] The everyday version is intermittent fasting and time-restricted eating.
The most important caveat comes from mice. A 2024 study put 960 genetically diverse female mice on 20% or 40% calorie restriction or on one or two fasting days a week. Eating less extended lifespan in proportion to the restriction, but genetics mattered more than diet. The traits that best predicted long life were holding onto body weight through stressful handling, keeping a high proportion of lymphocytes (a type of immune cell) and carrying more fat late in life. The deepest restriction extended life most but cost lean mass and shifted the immune system in ways that could raise susceptibility to infection, and the improvements in fasting glucose and body fat were not what tracked longer life. Intermittent fasting did not extend life in mice that started out heavy, and two fasting days a week went with disruption of the cells that make red blood cells.[35] The cohort was female only; a companion study of the same two-days-a-week fast in 800 mice of both sexes from 10 inbred strains found a modest gain in males and none in the inbred females, although the fast had lengthened life in the mixed-ancestry females of the original study.[36]
The lesson: better metabolic numbers don't guarantee a longer life if they come at the expense of muscle, lean mass and immune reserve.
Which amino acids matter: animal results that split by sex
What protein you eat tunes these pathways, not only how many calories. In rodents, restricting the single amino acid methionine extends lifespan by 30–40% regardless of total calorie intake.[37] The animal work is consistent across labs; the human trials are few, short and limited to metabolic markers.
- Branched-chain amino acids (leucine, isoleucine and valine) activate mTOR, and high levels have been linked to insulin resistance in humans and rodents. A lifelong low-BCAA diet raised median lifespan by about 32% in male mice but did not change female lifespan.[38] The harm of a high-BCAA diet is carried by isoleucine and valine; restricting leucine alone does almost nothing.[39] Restricting isoleucine extends lifespan in both sexes, more in males.[40] Restricting valine reduces frailty and cancer in both sexes but lengthens life only in males, by about 23% at the median.[41]
- Methionine restriction is thought to work partly by lowering the cell's methyl donor SAM (S-adenosylmethionine), which turns mTOR activity down and frees up autophagy.[42] In a blinded 8-week feeding trial, 59 adults with overweight or obesity were given all their food, low or high in methionine and cysteine. The low group lost about 1.14 kg more weight, but fasting insulin and glucose did not differ and the hormonal changes seen in animals did not appear, although an earlier 4-week study had reported them.[43]
Plant-forward eating is naturally lower in methionine and BCAAs than a meat-heavy diet, which is part of the science under dietary patterns.
The drugs: strong mechanisms, no human aging result
None of the drugs aimed at this hallmark has a trial showing it slows human aging, and the animal record is uneven: a 2025 meta-analysis of lifespan studies across eight vertebrate species found that rapamycin, but not metformin, significantly extended lifespan.[44] The class is compared on geroprotectors.
Rapamycin blocks mTOR and is the most reproducible drug lifespan-extender in animals. Daily high doses, as in transplant medicine, also hit a second mTOR complex and cause insulin resistance and immune suppression, so longevity use relies on low weekly doses, a schedule worked out in mice.[45] The human trials are small and unpromising:
- PEARL, described by its authors as the largest and longest trial of low-dose weekly rapamycin for healthy aging, ran 48 weeks in adults aged 50–85 and missed its primary endpoint, visceral fat. Its compounded drug delivered only about a third as much into the blood as standard generic sirolimus.[46]
- In 40 sedentary adults aged 65–85, 6 mg of standard sirolimus a week for 13 weeks did not add to the gains from a home exercise programme, and the rapamycin group logged more side effects (99 against 63 events).[47]
- Six weeks of two related drugs cut infections over the following year in 264 older adults,[48] but a phase 3 trial of one of those drugs in 1,024 adults found no fewer respiratory illnesses (26% against 25% on placebo).[49]
- Across 19 human studies, there were no serious drug-attributed side effects in healthy people, but more infections and higher cholesterol and triglycerides in people who already had age-related disease.[50]
Metformin switches on AMPK. The much-cited claim that people with diabetes on metformin outlive people without diabetes was contradicted by a Danish registry study that included twin pairs, where people starting metformin alone had higher mortality than people without diabetes.[51] In healthy adults aged 65 and over, it blunted the muscle gains from 14 weeks of resistance training.[52] TAME, the trial designed to test it against age-related disease, has never enrolled anyone: about $5 million from the US National Institute on Aging plus private pledges falls far short of its estimated $45–70 million cost.[53]
NAD⁺ precursors, NR (nicotinamide riboside) and NMN (nicotinamide mononucleotide), safely raise blood NAD⁺.[54] The benefits have not followed. In trials in adults averaging over 60, NMN did not improve muscle mass, grip strength, walking speed or chair-rise time, and NR was linked to worse physical-performance scores in people with mild cognitive impairment.[55] Pooling 15 NMN trials found it well tolerated but without effect on weight, blood sugar or blood fats.[56]
GLP-1 drugs such as semaglutide reduce nutrient load and moved several DNA-methylation clocks in one trial. It was a post-hoc, exploratory analysis of a 32-week trial in a narrow population (45 on semaglutide, 39 on placebo), and two authors work for a commercial epigenetic-testing company.[57] The drugs themselves are on GLP-1 drugs.
Protein and exercise: the levers you control
Protein needs may shift with age, but the evidence for a sharp switch is thin. The well-known age "flip" comes from one US survey analysis of 6,381 adults aged 50 and over, built on one day of recalled diet, in which high protein went with higher death rates between 50 and 65 and lower ones after 65.[58] A re-analysis of the same survey using estimates of usual intake found no link between protein and death at any age; its authors consult for the food industry.[59] In about 19,400 UK Biobank adults, at least 1.8 g of protein per kilogram of body weight a day went with about 36% more major cardiovascular events after 55 and no clear excess before, the opposite direction.[60] The case for more protein in older age rests on muscle and frailty, not on mortality data; the doses are on protein.
Exercise works the brakes with none of the drugs' problems, and harder effort works them more. In eight sedentary men, cycling at 80% of aerobic capacity raised AMPK activation 2.8-fold, while an easy bout at 40% that burned the same energy did not raise it measurably.[61] Training on an empty stomach adds little, if anything: one small crossover study found AMPK activation about 30% higher when fasted, and a later, more tightly controlled one found no difference.[62][63] Training also raises muscle levels of NAMPT, the enzyme that rebuilds NAD⁺, by about 1.46-fold on average across five human studies.[64] Zone 2 training is one good way to build the volume, but it is not the strongest AMPK stimulus; resistance training protects the muscle that restriction and age take.
What to actually do
- Ask for fasting insulin alongside fasting glucose at your next blood test, so HOMA-IR can be calculated.
- Avoid grazing around the clock and keep a feed–fast rhythm, a reasonable reading of the biology rather than something tested against aging. If you cut calories, cut moderately and aim for weight you can keep.
- Do regular resistance training, and include some harder aerobic efforts as well as easy volume.
- Keep protein adequate, especially past middle age. Through midlife, a plant-forward pattern keeps the mTOR-activating amino acids lower, which matters on animal evidence.
- Skip rapamycin, metformin and NAD⁺ boosters for longevity outside a trial.
Further reading
- López-Otín C, et al. The hallmarks of aging. Cell 2013.[65]
- López-Otín C, et al. Hallmarks of aging: an expanding universe. Cell 2023.[66]
- Tabák AG, et al. Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet 2009.[67]
- Rahmani J, et al. Association between IGF-1 levels ranges and all-cause mortality: A meta-analysis. Aging Cell 2022.[68]
- Waziry R, et al. Effect of long-term caloric restriction on DNA methylation measures of biological aging in healthy adults from the CALERIE trial. Nat Aging 2023 — post hoc analysis within a randomised trial.[69]
- Di Francesco A, et al. Dietary restriction impacts health and lifespan of genetically diverse mice. Nature 2024.[70]
- Yu D, et al. The adverse metabolic effects of branched-chain amino acids are mediated by isoleucine and valine. Cell Metab 2021.[71]
- Calubag MF, et al. Lifelong restriction of dietary valine has sex-specific benefits for health and lifespan in mice. Nat Aging 2026.[72]
- Moel M, et al. Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results. Aging 2025.[73]
- Ivimey-Cook ER, et al. Rapamycin, Not Metformin, Mirrors Dietary Restriction-Driven Lifespan Extension in Vertebrates: A Meta-Analysis. Aging Cell 2025.[74]
- Egan B, et al. Exercise intensity-dependent regulation of peroxisome proliferator-activated receptor coactivator-1 mRNA abundance is associated with differential activation of upstream signalling kinases in human skeletal muscle. J Physiol 2010.[75]
- Papanikolaou Y, et al. Animal and plant protein usual intakes are not adversely associated with all-cause, cardiovascular disease-, or cancer-related mortality risk: an NHANES III analysis. Appl Physiol Nutr Metab 2025.[76]